Aldhaeefi Mohammed, Alshaya Abdulrahman, Belrhiti Sanaa, Rungkitwattanakul Dhakrit
Department of Clinical and Administrative Pharmacy Sciences, College of Pharmacy, Howard University, Washington, DC, USA.
Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia.
Crit Care Explor. 2023 Jun 23;5(7):e0940. doi: 10.1097/CCE.0000000000000940. eCollection 2023 Jul.
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an infection. Septic shock is when initial fluid resuscitation fails to increase the mean atrial pressure to greater than or equal to 65 mm Hg. The 2021 Surviving Sepsis Campaign guidelines recommend corticosteroids for vasopressor and fluid-refractory septic shock patients. Medication shortages can arise, and their etiologies include natural disasters, quality control issues, and manufacturing discontinuation. The U.S. Food and Drug Administration and the American Society of Health-System Pharmacists announced a shortage of IV hydrocortisone. Methylprednisolone and dexamethasone are considered therapeutic alternatives to hydrocortisone. This commentary aims to guide clinicians on the alternative to hydrocortisone among septic shock patients due to medication shortage.
脓毒症是由宿主对感染的失调反应引起的危及生命的器官功能障碍。感染性休克是指初始液体复苏未能使平均动脉压升高至大于或等于65毫米汞柱。《2021年拯救脓毒症运动指南》推荐对使用血管活性药物和液体复苏无效的感染性休克患者使用皮质类固醇。药物短缺可能会出现,其病因包括自然灾害、质量控制问题和生产中断。美国食品药品监督管理局和美国卫生系统药师协会宣布静脉注射氢化可的松短缺。甲泼尼龙和地塞米松被认为是氢化可的松的治疗替代药物。本评论旨在指导临床医生在药物短缺情况下,为感染性休克患者选择氢化可的松的替代药物。